I Did Not Realize That!: Top Five S6 Kinase Of This Decade

Patients with a first diagnosis of HIV encephalopathy, interstitial lymphoid pneumonia or HIV-associated wasting syndrome were excluded from the analysis. Patients with a follow-up of LY294002 mw were generated with GraphPad Prism?5.0 software. Of the 8833 patients included in the PISCIS Cohort from January 1998 to December 2006, 625 HIV-infected, antiretroviral-na?ve individuals were eligible for the analysis (Fig.?1). The clinical characteristics and outcome are described in Table?1. Baseline clinical and demographic characteristics were broadly similar for patients starting HAART early or late (Table?1) and for each AIDS-defining condition analysed separately (data not shown). In a crude analysis, patients starting HAART in the late arm had significantly higher mortality than patients starting HAART in the early arm (p?0.004). A subanalysis of each AIDS-defining condition was also performed (see Materials and Methods and Tables?1 and 2). Patients with PCP at baseline (median CD4+ T-cell count, 28?cells/��L S6 Kinase IQR, (12�C53?cells/��L)) showed a significant advantage of starting HAART early, as mortality (2.1% in early starters and 15.8% in late starters, p?Lapatinib In late starters, a trend towards greater mortality was also observed (p?0.077). Patients with pulmonary TB starting HAART late had a trend towards higher mortality (p?0.066), whereas those with the extrapulmonary forms had similar mortality rates to those of patients starting HAART early or late (p?0.29). When OIs other than PCP and TB were analysed globally, patients showed a median CD4+ T-cell count of 45 (17�C127?cells/��L), and those who started HAART late had a greater probability of disease progression (p?0.041) and a trend towards a greater achievement of the combined endpoint AIDS/death (p?0.074).